For Immediate Release
Markham, Ontario – Nov 29, 2024 — Virotek Biosciences, a leading innovator in genomic testing and precision medicine, has been honored with the prestigious Innovation Category Award at Markham’s 34th Annual Business Excellence Awards. This recognition highlights Virotek’s groundbreaking contributions to cancer prevention, early detection, and personalized treatment.
Since relocating to Markham in 2022, Virotek has demonstrated an unwavering commitment to advancing precision oncology through innovative genomic solutions. Their ISO-15189-accredited laboratory has set new standards in clinical diagnostics by integrating cutting-edge research into global gene panels. These advancements allow Virotek to offer next-generation cancer screening and treatment planning at affordable prices compared to major global players, making personalized cancer care more accessible.
“This award is a testament to the dedication and passion of the entire Virotek team,” said Dr. Saeid Babaei, Chief Visionary Officer at Virotek Biosciences. “Innovation is at the heart of everything we do. We are honored to be recognized for our efforts to transform cancer care and improve patient outcomes worldwide. This achievement highlights Markham’s dynamic, knowledge-driven ecosystem and Southern Ontario’s role as a leading hub for fostering technological excellence.”
“This year’s Innovation Category Award truly showcases the incredible achievements of companies like Virotek Biosciences,” said Chris Collucci, President and CEO of the Markham Board of Trade. “Their commitment to advancing cancer screening and diagnostics with cutting-edge technologies exemplifies the type of forward-thinking businesses that thrive in Markham. We are proud to support such a dynamic organization and look forward to their continued success.”
The Innovation Category Award celebrates companies that drive market and technological advancements, positioning Virotek as a leader in the biotechnology and MedTech sectors. Moving forward, Virotek aims to continue its growth by enhancing its state-of-the-art wet lab facility in Markham, fostering collaboration, and expanding its outreach globally.
About Virotek Biosciences
Virotek Biosciences specializes in advanced genomic testing for cancer prevention, early detection, and treatment. With a mission to make personalized cancer care accessible and affordable, Virotek integrates cutting-edge research with clinical application to set new benchmarks in oncology diagnostics.
Media Contacts
Dr. Saeid Babaei — CEO
[email protected]